New procedure could reduce GERD symptoms without surgery

NCT ID NCT05570448

Recruiting now Disease control Sponsor: Midwest Veterans' Biomedical Research Foundation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new endoscopic procedure called anti-reflux mucosal ablation (ARAT) for people with chronic GERD. The procedure uses argon plasma coagulation to treat the lining of the stomach near the esophagus. 36 participants will be randomly assigned to receive either the real procedure or a sham procedure. The goal is to see if ARAT improves quality of life and reduces the need for daily acid-reducing medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-reflux mucosal ablation using argon plasma coagulation
What this could lead to: If successful, this procedure could offer a non-surgical option to reduce GERD symptoms and dependence on daily acid-reducing medications.
What could go wrong: This is a small, early-stage trial with only 36 participants. The procedure may not work better than a sham, and there are risks like bleeding or stricture.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRO ESOPHAGEAL REFLUX are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRO ESOPHAGEAL REFLUX

Contacts and locations

Locations

Kansas City VA Hospital
RECRUITING

Kansas City, Missouri, 64128, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.